Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GlaxoSmithKline Clicks With Crick

by Alex Scott
July 20, 2015 | A version of this story appeared in Volume 93, Issue 29

GlaxoSmithKline and London’s new Francis Crick Institute have agreed to co-develop treatments for diseases including HIV, malaria, and cancer. Both parties will contribute 10 researchers to the collaboration, which by 2016 aims to have up to 15 projects. GSK will provide the partnership with access to its library of 2 million compounds with interesting pharmaceutical properties. The two will work together in GSK’s R&D center in Stevenage, just north of London, and also at Crick’s $1 billion center after it opens in London later this year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.